- Home
- MCR vs CLYM Comparison
MCR vs CLYM Comparison
Compare MCR & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- CLYM
- Stock Information
- Founded
- MCR 1989
- CLYM 2018
- Country
- MCR United States
- CLYM United States
- Employees
- MCR N/A
- CLYM N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- CLYM
- Sector
- MCR Finance
- CLYM
- Exchange
- MCR Nasdaq
- CLYM NYSE
- Market Cap
- MCR 263.0M
- CLYM 242.8M
- IPO Year
- MCR N/A
- CLYM 2021
- Fundamental
- Price
- MCR $6.17
- CLYM $3.01
- Analyst Decision
- MCR
- CLYM
- Analyst Count
- MCR 0
- CLYM 0
- Target Price
- MCR N/A
- CLYM N/A
- AVG Volume (30 Days)
- MCR 66.7K
- CLYM 338.5K
- Earning Date
- MCR 01-01-0001
- CLYM 11-12-2024
- Dividend Yield
- MCR 8.52%
- CLYM N/A
- EPS Growth
- MCR N/A
- CLYM N/A
- EPS
- MCR 0.38
- CLYM N/A
- Revenue
- MCR N/A
- CLYM N/A
- Revenue This Year
- MCR N/A
- CLYM N/A
- Revenue Next Year
- MCR N/A
- CLYM N/A
- P/E Ratio
- MCR $16.61
- CLYM N/A
- Revenue Growth
- MCR N/A
- CLYM N/A
- 52 Week Low
- MCR $5.63
- CLYM $2.35
- 52 Week High
- MCR $6.70
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- MCR 27.76
- CLYM N/A
- Support Level
- MCR $6.30
- CLYM N/A
- Resistance Level
- MCR $6.42
- CLYM N/A
- Average True Range (ATR)
- MCR 0.05
- CLYM 0.00
- MACD
- MCR -0.02
- CLYM 0.00
- Stochastic Oscillator
- MCR 1.92
- CLYM 0.00
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income. The fund invests the assets in debt instruments. It invests the assets in corporate bonds of U.S. and foreign issuers, U.S. Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S. and foreign issuers, and debt instruments of issuers located in emerging market countries.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.